A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
This article was originally published in PharmAsia News
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
You may also be interested in...
Nestlé’s announcement on May 24 that its new health sciences subsidiary is buying Prometheus Laboratories, a gastrointestinal drug and diagnostic company, takes the food company in a new direction, but also raises questions for pharma.
Nestle Health Science will add gastrointestinal diagnostic services to its nutritional health business by acquiring Prometheus Laboratories for undisclosed terms in a deal announced May 24.
Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note